HIV and smoking: Associated risks and prevention strategies

HIV/AIDS - Research and Palliative Care

Volumn 8, Issue , 2015, Pages 17-36

  Kariuki, Wanjiku ^a   Manuel, Jennifer I ^b   Kariuki, Ngaruiya ^c   Tuchman, Ellen ^b   O’Neal, Johnnie ^d   Lalanne, Genevieve A ^b  

^a UNIVERSITY OF TEXAS SCHOOL OF PUBLIC HEALTH   (United States)

^b NEW YORK UNIVERSITY   (United States)

^c MAIMONIDES MEDICAL CENTER   (United States)

^d The College of New Rochelle   (United States)

Author keywords

AIDS; Health risks; HIV; Smoking; Smoking cessation interventions

Indexed keywords

ALCOHOL; AMFEBUTAMONE; ANTIRETROVIRUS AGENT; EFAVIRENZ; NICOTINE; NICOTINE GUM; NICOTINE LOZENGE; NICOTINE PATCH; NORTRIPTYLINE; PLACEBO; VARENICLINE; VENLAFAXINE;

ABNORMAL DREAMING; ALCOHOL CONSUMPTION; BEHAVIOR THERAPY; CARDIOVASCULAR DISEASE; COGNITIVE DEFECT; COGNITIVE THERAPY; COMORBIDITY; COUNSELING; DISEASE COURSE; DRUG ABUSE; DRUG DOSE TITRATION; DRUG EFFECT; DRUG EFFICACY; DRUG RESPONSE; DRUG WITHDRAWAL; ELECTRONIC CIGARETTE; HEALTH CARE ACCESS; HIGH RISK POPULATION; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOPATHOLOGY; INFECTION PREVENTION; INFECTION RISK; ISCHEMIC HEART DISEASE; LUNG DISEASE; MENTAL DISEASE; MOOD DISORDER; MORBIDITY; MORTALITY; MOTIVATIONAL INTERVIEWING; NAUSEA; NICOTINE REPLACEMENT THERAPY; QUALITY OF LIFE; RECURRENCE RISK; RELAXATION TRAINING; RESTLESSNESS; REVIEW; RISK REDUCTION; SLEEP DISORDER; SMOKING; SMOKING CESSATION; SOCIAL NETWORK; SOCIAL SUPPORT; SUBSTANCE ABUSE; SUICIDAL IDEATION; TOBACCO DEPENDENCE;

EID: 84953249867     PISSN: None     EISSN: 11791373     Source Type: Journal    
DOI: 10.2147/HIV.S56952     Document Type: Review

References (88)

1. Mokdad AH, Marks JS, Stroup DF, Gerberding JL. Actual causes of death in the United States. JAMA. 2004;291:1238-1245.
2. Crothers K, Goulet JL, Rodriguez-Barradas MC, et al. Impact of cigarette smoking on mortality in HIV-positive and HIV-negative veterans. AIDS Educ Prev. 2009;21(3 Suppl):40-53.
3. Lifson AR, Neuhaus J, Arribas JR, van den Berg-Wolf M, Labriola AM, Read TR. Smoking-related health risks among persons with HIV in the strategies for management of antiretroviral therapy clinical trial. Am J Public Health. 2010;100(10):1896-1903.
4. Tesoriero JM, Gieryic SM, Carrascal A, Lavigne HE. Smoking among HIV-positive New Yorkers: prevalence, frequency, and opportunities for cessation. AIDS Behav. 2010;14(4):824-835.
5. Burkhalter JE, Springer CM, Chhabra R, Ostroff JS, Rapkin BD. Tobacco use and readiness to quit smoking in low-income HIV-infected persons. Nicotine Tob Res. 2005;7(4):511-522.
6. Gritz ER, Vidrine DJ, Lazev AB, Amick BC 3rd, Arduino RC. Smoking behavior in a low-income multiethnic HIV/AIDS population. Nicotine Tob Res. 2004;6(1):71-77.
7. Benard A, Bonnet F, Tessier JF, et al. Tobacco addiction and HIV infection: Toward the implementation of cessation programs. ANRS CO3 Aquitaine cohort. AIDS Patient Care STDS. 2007;21(7):458-468.
8. Lloyd-Richardson EE, Stanton CA, Papandonatos GD, et al. Motivation and patch treatment for HIV+ smokers: A randomized controlled trial. Addiction. 2009;104(11):1891-1900.
9. Helleberg M, Afzal S, Kronborg G, et al. Mortality attributable to smoking among HIV-1-infected individuals: A nationwide, population-based cohort study. Clin Infect Dis. 2013;56(5):727-734.
10. Centers for Disease Control and Prevention. Best practices for comprehensive tobacco control programs - 2007. Atlanta, GA: National Center for Chronic Disease Prevention and Health Promotion, Office of Smoking and Health; 2007. Available from: ftp://ftp.cdc.gov/pub/fda/fda/BestPractices_Complete.pdf. Accessed October 25, 2015.
11. US Department of Health and Human Services. How tobacco smoke causes disease: The biology and behavioral basis for smoking-attributable disease: A report of the surgeon general. USDHHS, Centers for Disease Control and Prevention, National Center for Chronic Disease Prevention and Health Promotion, Office on Smoking and Health; 2010. Available from: http://www.cdc.gov/tobacco/data_statistics/sgr/2010/. Accessed October 25, 2015.
12. Burns DN, Kramer A, Yellin F, et al. Cigarette smoking: a modifier of human immunodeficiency virus type 1 infection? J Acquir Immune Defic Syndr. 1991;4(1):76-83.
13. Zhao L, Li F, Zhang Y, et al. Mechanisms and genes involved in enhancement of HIV infectivity by tobacco smoke. Toxicology. 2010;278(2):242-248.
14. Marshall MM, McCormack MC, Kirk GD. Effect of cigarette smoking on HIV acquisition, progression, and mortality. AIDS Educ Prev. 2009;21(3 Suppl):28-39.
15. Royce RA, Winkelstein W Jr. HIV infection, cigarette smoking and CD4 T-lymphocyte counts: Preliminary results from the San Francisco men's health study. AIDS. 1990;4(4):327-334.
16. Feldman JG, Minkoff H, Schneider MF, et al. Association of cigarette smoking with HIV prognosis among women in the HAART era: a report from the women's interagency HIV study. Am J Public Health. 2006;96(6):1060-1065.
17. Valiathan R, Miguez MJ, Patel B, Arheart KL, Asthana D. Tobacco smoking increases immune activation and impairs T-cell function in HIV infected patients on antiretrovirals: A cross-sectional pilot study. PLoS One. 2014;9(5):e97698.
18. Luu HN, Amirian ES, Scheurer ME. The interaction between smoking status and highly active antiretroviral therapy (HAART) use on the risk of kaposi's sarcoma (KS) in a cohort of HIV-infected men. Br J Cancer. 2013;108(5):1173-1177.
19. Hoover DR, Black C, Jacobson LP, et al. Epidemiologic analysis of kaposi's sarcoma as an early and later AIDS outcome in homosexual men. Am J Epidemiol. 1993;138(4):266-278.
20. Daling JR, Madeleine MM, Johnson LG, et al. Human papillomavirus, smoking, and sexual practices in the etiology of anal cancer. Cancer. 2004;101(2):270-280.
21. Clifford GM, Polesel J, Rickenbach M, et al. Cancer risk in the swiss HIV cohort study: Associations with immunodeficiency, smoking, and highly active antiretroviral therapy. J Natl Cancer Inst. 2005;97(6):425-432.
22. Palefsky JM, Minkoff H, Kalish LA, et al. Cervicovaginal human papillomavirus infection in human immunodeficiency virus-1 (HIV)-positive and high-risk HIV-negative women. J Natl Cancer Inst. 1999;91(3): 226-236.
23. Brockmeyer N, Kreuter A, Pfister H, Altmeyer P, Wieland U. Elevated anal HPV16 DNA loads in HIV+ men who smoke. Paper presented at: The 14th conference on retroviruses and opportunistic infections; February 2007. Fourteenth Conference on Retroviruses and Opportunistic Infections, Los Angeles, abstract 872, 2007.
24. Vidrine DJ. Cigarette smoking and HIV/AIDS: Health implications, smoker characteristics and cessation strategies. AIDS Educ Prev. 2009;21(3 Suppl):3-13.
25. Pence BW, Miller WC, Whetten K, Eron JJ, Gaynes BN. Prevalence of DSM-IV-defined mood, anxiety, and substance use disorders in an HIV clinic in the southeastern united states. J Acquir Immune Defic Syndr. 2006;42(3):298-306.
26. Michel L, Carrieri MP, Fugon L, et al. Harmful alcohol consumption and patterns of substance use in HIV-infected patients receiving antiretrovirals (ANRS-EN12-VESPA study): relevance for clinical management and intervention. AIDS Care. 2010;22(9):1136-1145.
27. Shuter J, Bernstein SL, Moadel AB. Cigarette smoking behaviors and beliefs in persons living with HIV/AIDS. Am J Health Behav. 2012; 36(1):75-85.
28. Mdodo R, Frazier EL, Dube SR, et al. Cigarette smoking prevalence among adults with HIV compared with the general adult population in the United States. Ann Intern Med. 2015;162(5):335-348.
29. Reisen CA, Bianchi FT, Cohen-Blair H, et al. Present and past influences on current smoking among HIV-positive male veterans. Nicotine Tob Res. 2011;13(8):638-645.
30. Bryant VE, Kahler CW, Devlin KN, Monti PM, Cohen RA. The effects of cigarette smoking on learning and memory performance among people living with HIV/AIDS. AIDS Care. 2013;25(10):1308-1316.
31. Durazzo TC, Rothlind JC, Cardenas VA, Studholme C, Weiner MW, Meyerhoff DJ. Chronic cigarette smoking and heavy drinking in human immunodeficiency virus: consequences for neurocognition and brain morphology. Alcohol. 2007;41(7):489-501.
32. Cui Q, Carruthers S, McIvor A, Smaill F, Thabane L, Smieja M. Effect of smoking on lung function, respiratory symptoms and respiratory diseases amongst HIV-positive subjects: a cross-sectional study. AIDS Res Ther. 2010;7:6.
33. van Zyl-Smit RN, Brunet L, Pai M, Yew W. The convergence of the global smoking, COPD, tuberculosis, HIV, and respiratory infection epidemics. Infect Dis Clin North Am. 2010;24(3):693-703.
34. Petrache I, Diab K, Knox KS, et al. HIV associated pulmonary emphysema: A review of the literature and inquiry into its mechanism. Thorax. 2008;63(5):463-469.
35. Palacios R, Pascual J, Cabrera E, et al. Lung cancer in HIV-infected patients. Int J STD AIDS. 2014;25(4):239-243.
36. Triant VA. HIV infection and coronary heart disease: an intersection of epidemics. J Infect Dis. 2012;205 Suppl 3:S355-S361.
37. Bekele T, Rourke SB, Tucker R, et al. Direct and indirect effects of perceived social support on health-related quality of life in persons living with HIV/AIDS. AIDS Care. 2013;25(3):337-346.
38. Degroote S, Vogelaers D, Vandijck D. What determines health-related quality of life among people living with HIV: an updated review of the literature. Arch Public Health. 2014;72(1):40.
39. Rahmanian S, Wewers M, Koletar S, Reynolds N, Ferketich A, Diaz P. Cigarette smoking in the HIV-infected population. Proc Am Thorac Soc. 2011;8(3):313-319.
40. Turner J, Page-Shafer K, Chin DP, Osmond D, Mossar M, Markstein L, Huitsing J, Barnes S, Clemente V, Chesney M. Adverse impact of cigarette smoking on dimensions of health-related quality of life in persons with HIV infection. AIDS Patient Care STDS. 2001;15(12):615-624.
41. US Department of Health and Human Services. Treating tobacco use and dependence: 2008 update. Clinical practice guideline. Rockville, MD: US Department of Health and Human Services; 2008.
42. Ciccolo JT, Busch AM. Behavioral interventions to enhance smoking cessation: A summary of current evidence. Am J Lifestye Med. 2014;9:92-104.
43. Lancaster T, Stead LF. Individual behavioral counselling for smoking cessation. Cochrane Database Syst Rev. 2005;18(2):CD001292.
44. Nahvi S, Cooperman NA. Review: the need for smoking cessation among HIV-positive smokers. AIDS Educ Prev. 2009;21(3 Suppl):14-27.
45. Niaura R, Chander G, Hutton H, Stanton C. Interventions to address chronic disease in HIV: Strategies to promote smoking cessation among HIV-infected individuals. Curr HIV/AIDS Rep. 2012;9(4):375-384.
46. Moscou-Jackson G, Commodore-Mensah Y, Farley J, DiGiacomo M. Smoking-cessation interventions in people living with HIV infection: A systematic review. J Assoc Nurses AIDS Care. 2014;25(1):32-45.
47. Kwong J, Bouchard-Miller K. Smoking cessation for persons living with HIV: A review of currently available interventions. J Assoc Nurses AIDS Care. 2010;21(1):3-10.
48. Reus VI, Smith BJ. Multimodal techniques for smoking cessation: a review of their efficacy and utilisation and clinical practice guidelines. Int J Clin Pract. 2008;62(11):1753-1768.
49. Manuel JK, Lum PJ, Hengl NS, Sorensen JL. Smoking cessation interventions with female smokers living with HIV/AIDS: A randomized pilot study of motivational interviewing. AIDS Care. 2013;25(7):820-827.
50. Lazev A, Vidrine D, Arduino R, Gritz E. Increasing access to smoking cessation treatment in a low-income, HIV-positive population: the feasibility of using cellular telephones. Nicotine Tob Res. 2004;6(2): 281-286.
51. Tornero C, Mafe C. Varenicline and antiretroviral therapy in patients with HIV. J Acquir Immune Defic Syndr. 2009;52(5):656.
52. Stead LF, Perera R, Bullen C. Nicotine replacement therapy for smoking cessation. Cochrane Database Syst Rev. 2012;11:CD000146.
53. Bohadana A, Nilsson F, Rasmussen T, Martinet Y. Nicotine inhaler and nicotine patch as a combination therapy for smoking cessation: a randomized, double-blind, placebo-controlled trial. Arch Intern Med. 2000;160(20):3128-3134.
54. Westman E, Tomlin K, Rose J. Combining the nicotine inhaler and nicotine patch for smoking cessation. Am J Health Behav. 2000;24(2):114-119.
55. Etter JF. Electronic cigarettes: a survey of users. BMC Public Health. 2010;10:231.
56. Bullen C, Howe C, Laugesen M, et al. Electronic cigarettes for smoking cessation: A randomized controlled trial. Lancet. 2013;382(9905): 1629-1637.
57. Trtchounian A, Williams M, Talbot P. Conventional and electronic cigarettes (e-cigarettes) have different smoking characteristics. Nicotine Tob Res. 2010;12(9):905-912.
58. Goniewicz ML, Knysak J, Gawron M, et al. Levels of selected carcinogens and toxicants in vapour from electronic cigarettes. Tob Control. 2014;23(2):133-139.
59. Burstyn I. Peering through the mist: Systematic review of what the chemistry of contaminants in electronic cigarettes tells us about health risks. BMC Public Health. 2014;14:18.
60. DeSilva KE, Le Flore DB, Marston BJ, Rimland D. Serotonin syndrome in HIV-infected individuals receiving antiretroviral therapy and fluoxetine. AIDS. 2001;15(10):1281-1285.
61. Aubin HJ, Bobak A, Britton JR, et al. Varenicline versus transdermal nicotine patch for smoking cessation: results from a randomised open-label trial. Thorax. 2008;63(8):717-724.
62. Gonzales D, Rennard SI, Nides M, et al. Varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, vs sustained-release bupropion and placebo for smoking cessation: A randomized controlled trial. JAMA. 2006;296(1):47-55.
63. Jorenby DE, Hays JT, Rigotti NA, et al. Efficacy of varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, vs placebo or sustained-release bupropion for smoking cessation: A randomized controlled trial. JAMA. 2006;296(1):56-63.
64. Gunnell D, Irvine D, Wise L, Davies C, Martin RM. Varenicline and suicidal behaviour: a cohort study based on data from the general practice research database. BMJ. 2009;339:b3805.
65. Ferketich AK, Diaz P, Browning KK, et al. Safety of varenicline among smokers enrolled in the lung HIV study. Nicotine Tob Res. 2013;15(1): 247-254.
66. Singh S, Loke YK, Spangler JG, Furberg CD. Risk of serious adverse cardiovascular events associated with varenicline: A systematic review and meta-analysis. CMAJ. 2011;183(12):1359-1366.
67. Lip Shultz SE, Mas CM, Henkel JM, Franco VI, Fisher SD, Miller TL. HAART to heart: Highly active antiretroviral therapy and the risk of cardiovascular disease in HIV-infected or exposed children and adults. Expert Rev Anti Infect There. 2012;10(6):661-674.
68. Ingersoll KS, Crapsey KL, Heckman CJ. A test of motivational plus nicotine replacement interventions for HIV positive smokers. AIDS Behav. 2009;13(3):545-554.
69. Moadel AB, Bernstein SL, Murmelstein RJ, Aronstein JH, Dolce EH, Shuter J. A randomized controlled trial of a tailored group smoking cessation intervention for HIV-infected smokers. J Acquir Immune Defic Syndr. 2012;61(2):208-215.
70. Vidrine DJ, Arduino RC, Gritz ER. Impact of a cell phone intervention on mediating mechanisms of smoking cessation in individuals living with HIV/AIDS. Nicotine Tob Res. 2006;8 Suppl 1:S103-S108.
71. Vidrine DJ, Marks RM, Arduino RC, Gritz ER. Efficacy of cell phone-delivered smoking cessation counseling for persons living with HIV/AIDS: 3-month outcomes. Nicotine Tob Res. 2012;14(1):106-110.
72. Humfleet GL, Hall SM, Bellocchi KL, Dilley JW. A randomized clinical trial of smoking cessation treatments provided in HIV clinical care settings. Nicotine Tob Res. 2013;15(8):1436-1445.
73. Elzi L, Spore D, Voggensperger J, et al. A smoking cessation programme in HIV-infected individuals: A pilot study. Antivir Ther. 2006;11(6):787-795.
74. Wewers ME, Needing JL, Kihm KE. The feasibility of a nurse-managed, peer-led tobacco cessation intervention among HIV-positive smokers. J Assoc Nurses AIDS Care. 2000;11(6):37-44.
75. Fuster M, Estrada V, Fernandez-Pinilla MC, et al. Smoking cessation in HIV patients: Rate of success and associated factors. HIV Med. 2009;10(10):614-619.
76. Cui Q, Robinson L, Elston D, et al. Safety and tolerability of varenicline tartrate (Champix(®)/Chantix(®)) for smoking cessation in HIV-infected subjects: a pilot open-label study. AIDS Patient Care STDS. 2012;26(1):12-19.
77. Chew D, Steinberg MB, Thomas P, Swaminathan S, Hodder SL. Evaluation of a smoking cessation program for HIV infected individuals in an urban HIV clinic: Challenges and lessons learned. AIDS Res Treat. 2014;2014:237834.
78. Cummins D, Trotter G, Moussa M, Turham G. Smoking cessation for clients who are HIV-positive. Nurs Stand. 2005;20(12):41-47.
79. Matthews AK, Conrad M, Kuhns L, Vargas M, King AC. Project exhale: Preliminary evaluation of a tailored smoking cessation treatment for HIV-positive African American smokers. AIDS Patient Care STDS. 2013;27(1):22-32.
80. Webb MS, Vanable PA, Carey MP, Blair DC. Cigarette smoking among HIV men and women: Examining health, substance use, and psychosocial correlates across the smoking spectrum. J Behav Med. 2007;30(5):371-383.
81. Ingersoll K. The impact of psychiatric symptoms, drug use, and medication regimen on non-adherence to HIV treatment. AIDS Care. 2004;16(2):199-211.
82. Ingersoll KS, Heckman CJ. Patient-clinician relationships and treatment system effects on HIV medication adherence. AIDS Behav. 2005;9(1):89-101.
83. Leserman J, Ironson G, O'Cleirigh C, Fordiani JM, Balbin E. Stressful life events and adherence in HIV. AIDS Patient Care STDS. 2008;22(5):403-411.
84. Arnsten JH, Li X, Mizuno Y, et al. Factors associated with antiretroviral therapy adherence and medication errors among HIV-infected injection drug users. J Acquir Immune Defic Syndr. 2007;46 Suppl 2:S64-S71.
85. Reynolds NR. Cigarette smoking and HIV: More evidence for action. AIDS Educ Prev. 2009;21(3 Suppl):106-121.
86. Humfleet GL, Delucchi K, Kelley K, Hall SM, Dilley J, Harrison G. Characteristics of HIV-positive cigarette smokers: A sample of smokers facing multiple challenges. AIDS Educ Prev. 2009;21(3 Suppl):54-64.
87. Cox LS, Okuyemi K, Choi WS, Ahluwalia JS. A review of tobacco use treatments in US ethnic minority populations. Am J Health Promot. 2011;25(5 Suppl):S11-S30.
88. Cargill VA, Stone VE. HIV/AIDS: a minority health issue. Med Clin North Am. 2005;89(4):895-912.